Perrigo Company plc Prepaid Expense and Other Assets, Current
Perrigo Company plc (PRGO) had Prepaid Expense and Other Assets, Current of $277.70 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-27: Prepaid Expense and Other Assets, Current $277.70M.
- 2026-03-28: Prepaid Expense and Other Assets, Current $272.20M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $231.40M.
- 2025-09-27: Prepaid Expense and Other Assets, Current $295.20M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-27 | $277.70M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $272.20M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $231.40M 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $295.20M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $267.10M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | $229.00M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $199.00M 10-K · filed 2026-02-26 | |
| 2024-09-28 | $311.60M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | $281.80M 10-Q · filed 2024-08-02 | |
| 2024-03-30 | $246.60M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $201.10M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $279.70M 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $296.20M 10-Q · filed 2023-08-08 | |
| 2023-04-01 | $266.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $271.80M 10-K · filed 2024-02-27 | |
| 2022-10-01 | $321.70M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | $336.30M 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $268.30M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $305.80M 10-K · filed 2023-02-28 | |
| 2021-10-02 | $355.70M 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $277.30M 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $251.50M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $182.20M 10-K · filed 2022-03-01 | $237.60M 10-K · filed 2021-03-01 |
| 2020-09-26 | $350.50M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $311.30M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $308.30M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $165.80M 10-K · filed 2021-03-01 | $192.10M 10-K · filed 2020-02-27 |
| 2019-09-28 | $248.60M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $322.10M 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $139.80M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $400.00M 10-K · filed 2020-02-27 | |
| 2018-09-29 | $359.50M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $238.40M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $246.20M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $203.20M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $297.40M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $176.50M 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $185.20M 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $212.00M 10-K · filed 2018-03-01 | |
| 2016-10-01 | $250.60M 10-Q/A · filed 2017-05-23 | |
| 2016-07-02 | $297.30M 10-Q/A · filed 2017-05-22 | |
| 2016-04-02 | $332.60M 10-Q/A · filed 2017-05-22 | |
| 2015-12-31 | $286.10M 10-K · filed 2018-03-01 | $289.10M 10-KT · filed 2016-02-25 |
| 2015-09-26 | $168.60M 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $150.10M 10-K · filed 2017-05-22 | $141.30M 10-K · filed 2015-08-13 |
| 2015-03-28 | $89.20M 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $115.00M 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $130.10M 8-K · filed 2014-11-20 | |
| 2014-06-28 | $121.90M 10-K · filed 2017-05-22 | $116.00M 10-K · filed 2014-08-14 |
| 2014-03-29 | $60.20M 10-Q · filed 2014-05-07 | |
| 2013-12-28 | $66.50M 10-Q · filed 2014-02-06 | |
| 2013-09-28 | $20.04K 10-Q · filed 2013-11-04 | |
| 2013-06-29 | $54.10M 10-K · filed 2014-08-14 | $0.00 10-Q · filed 2013-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |